ζ-Stat trisodium is a specific and atypical inhibitor of PKC-ζ (IC50 = 5 μM), exhibiting anti-tumor activity in vitro by reducing proliferation and inducing apoptosis in melanoma cell lines. It significantly inhibits PKC-ζ activity (51% inhibition at 5 μM) with minimal effect on PKC-ι (13% inhibition at 20 μM). ζ-Stat trisodium decreases cell proliferation in SK-MEL-2 and MeWo cells in a concentration-dependent manner (0.1–10 μM, 3 days). In combination with 5-FU, it reduces viability of LoVo colorectal cancer (CRC) cells by more than 75% (7 or 10 μM, 24–72 h). It also downregulates phosphorylated and total PKC-ζ, Bcl-2, and PARP levels while increasing Caspase-3 and cleaved-PARP levels in SK-MEL-2 and MeWo cells (5 μM, 3 days).